BLLN BillionToOne, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 2070849 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY71.9%
TTM net income YoY593.9%
TTM EPS YoY183.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin71.4%
Operating margin10.2%
Net margin11.3%
FCF margin7.8%
EBITDA margin11.9%
Returns
ROE30.2%
ROA9.1%
ROIC (approx.)—
Asset turnover0.80x
Leverage & solvency
Liabilities / assets25.5%
Debt / equity0.16x
Current ratio11.25x
Interest coverage1,655.26x
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio0.3%
Payout ratio—
Capex / revenue3.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $122.98M | $109.45M | $108.39M | $96.05M | $83.52M | $66.57M | $58.96M | $45.08M |
| Cost of revenue | $35.84M | $32.34M | $29.29M | $27.45M | $25.11M | $23.11M | $20.99M | $19.36M |
| Gross profit | $87.14M | $77.11M | $79.10M | $68.60M | $58.42M | $43.47M | $37.97M | $25.72M |
| R&D expense | $20.22M | $17.32M | $14.69M | $14.25M | $12.95M | $11.75M | $10.43M | $11.00M |
| SG&A expense | $55.91M | $54.29M | $46.57M | $44.02M | $35.83M | $33.34M | $29.86M | $26.41M |
| Operating income | $11.02M | $5.50M | $17.83M | $10.33M | $9.63M | -$1.63M | -$2.31M | -$11.69M |
| Interest expense | $6,000 | $8,000 | $10,000 | $3,000 | $20,000 | $32,000 | $40,000 | $47,000 |
| Pretax income | $17.39M | $7.52M | $18.51M | $6.30M | $5.58M | -$232,000 | -$3.89M | -$11.45M |
| Income tax | $1,300 | -$536,000 | $539,000 | $320,000 | -$129,000 | $14,500 | $100,000 | $24,000 |
| Net income | $17.39M | $8.05M | $17.97M | $5.98M | $5.71M | -$246,000 | -$3.99M | -$11.48M |
| EBITDA | $13.00M | $7.33M | $19.57M | $12.00M | $11.32M | $120,000 | -$522,000 | -$9.93M |
| EPS (basic) | 0.37 | 0.17 | 0.39 | — | 0.14 | -0.02 | -0.39 | — |
| EPS (diluted) | 0.32 | 0.15 | 0.34 | — | 0.10 | -0.02 | -0.39 | — |
| Weighted avg. shares (diluted) | 53.73M | 54.46M | 53.03M | — | 15.57M | 10.38M | 10.31M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $561.51M | $548.63M | $537.45M | $495.98M | $195.15M | $188.96M | $191.60M | $191.48M |
| Receivables | $88.28M | $74.89M | $61.30M | $41.62M | $34.65M | — | — | $24.71M |
| Inventory | $21.89M | $21.14M | $19.22M | $17.55M | $17.39M | — | — | $8.73M |
| Current assets | $682.09M | $651.38M | $624.14M | $560.56M | $251.72M | — | — | $227.82M |
| PP&E, net | $26.78M | $24.93M | $22.28M | $20.36M | $18.67M | — | — | $17.11M |
| Total assets | $760.49M | $729.70M | $700.73M | $632.65M | $327.52M | — | — | $302.06M |
| Current liabilities | $60.64M | $55.73M | $57.16M | $47.96M | $40.78M | — | — | $28.39M |
| Short-term debt | — | — | — | $0 | — | — | — | $0 |
| Long-term debt | $88.98M | $91.03M | $90.00M | $57.23M | $54.99M | — | — | $51.48M |
| Total debt | $88.98M | $91.03M | $90.00M | $57.23M | $54.99M | — | — | $51.48M |
| Total liabilities | $193.94M | $192.89M | $195.11M | $152.55M | $147.62M | — | — | $134.31M |
| Shareholders' equity | $566.55M | $536.81M | $505.62M | $480.11M | -$239.51M | -$250.25M | -$252.91M | -$251.66M |
| Net debt | -$472.53M | -$457.60M | -$447.44M | -$438.75M | -$140.17M | — | — | -$140.00M |
| Shares outstanding | — | — | — | — | 11.18M | — | — | 10.93M |
| Cash flow statement | ||||||||
| Operating cash flow | $12.55M | $9.14M | $15.43M | $10.79M | $10.00M | $1.18M | $2.62M | -$8.42M |
| Capital expenditure | $3.95M | $4.05M | $4.47M | $1.54M | $2.12M | $2.87M | $2.35M | $2.07M |
| Free cash flow | $8.60M | $5.09M | $10.96M | $9.26M | $7.87M | -$1.69M | $278,000 | -$10.50M |
| Investing cash flow | -$3.95M | -$4.05M | -$4.47M | -$1.58M | -$2.12M | -$2.87M | -$2.35M | -$2.10M |
| Financing cash flow | $4.28M | $6.09M | $30.52M | $291.61M | -$1.68M | -$949,000 | -$156,000 | -$288,000 |
| Depreciation & amortization | $1.97M | $1.83M | $1.74M | $1.67M | $1.69M | $1.75M | $1.79M | $1.76M |
| Stock-based compensation | $9.70M | $8.22M | $6.51M | $6.33M | $4.47M | $2.73M | $2.37M | $2.31M |
| Share buybacks | — | — | — | $0 | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 9 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.